Amylin Pharmaceuticals to Present at the 4th Annual BIOCOM Investor Conference
SAN DIEGO, CA, Oct. 22, 2009 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 4th Annual BIOCOM Investor Conference in San Diego on Monday, October 26, 2009 at 9:30 a.m. PT / 12:30 p.m. ET. David Maggs, M.D., vice president of research and development strategic relations, will be providing a corporate overview.
The audio portion of the presentation will be webcast and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate Web site, located at www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
